AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03320187
Drug: Dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dinoprostone 3gm vaginal tablet will be used as the study method of labor induction
Trial: NCT03100318
Drug: FYU-981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral daily dosing for 14 weeks
Trial: NCT03245346
Drug: GEA
RxNorm normalized name: Geangin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural catheterization will be performed and epidural anesthesia will be maintained with 0.25% ropivacaine during surgery. General anesthesia will be maintained with inhalation (sevoflurane) and muscle relaxants will be administered when considered necessary.
Trial: NCT03245346
Drug: PCEA
RxNorm normalized name: Patient-Controlled Epidural Analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled epidural analgesia (0.15% ropivacaine infusion) will be provided after surgery.
Trial: NCT01001351
Drug: PRT-201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied topically during surgery.
Trial: NCT01001351
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied topically during surgery
Trial: NCT02852967
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matching belumosudil
Trial: NCT05940506
Drug: KX-826-2.5 mg (0.25%)/60 mL BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered once in the morning and once in the evening.
Trial: NCT05940506
Drug: KX-826-5 mg (5%)/60 mL QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered in the evening once daily.
Trial: NCT05940506
Drug: KX-826-5 mg (5%)/60 mL BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered once in the morning and once in the evening.
Trial: NCT01273402
Drug: TF2/IMP288
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TF2 is administered 4 days prior to radiolabeled IMP288. Each are given weekly for 2 weeks.
Trial: NCT04286152
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A sugar pill manufactured to mimic Mirabegron 50 mg tablet is administered to patients PO once a day for 7 days from stent insertion until removal
Trial: NCT04015245
Drug: Stronger Neo-Minophagen C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous injection after TACE
Trial: NCT03460652
Drug: KP415 oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily oral dose
Trial: NCT01030120
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02631954
Drug: Vfend®(Voriconazole) IV 200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vfend®(Voriconazole) IV 200mg to administered intravenously once
Trial: NCT01747915
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, either liquid or capsule, dosed twice daily beginning at Randomization to End of Study/Early Termination.
Trial: NCT00737724
Drug: Deferred RV and antiMTB treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receives only antituberculosis therapy and 2 months afterwards antiretroviral therapy
Trial: NCT00670566
Drug: irbesartan/hydrochlorothiazide
RxNorm normalized name: irbesartan/hydrochlorothiazide 300 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50/12.5mg for 4 weeks follow 300/12.5mg for 4 weeks and proceed to 300/25mg for 4 weeks
Trial: NCT04327232
Drug: Spironolactone 25mg
RxNorm normalized name: SPIRONOLACTONE 25MG TAB
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mineralocorticoid Receptor Antagonists
Trial: NCT04327232
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00002631
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00803738
Drug: Terazol Vaginal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal Suppository inserted intravaginally once daily before bedtime for 3 consecutive days
Trial: NCT00650052
Drug: Zonegran® Capsules 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg, single dose fasting
Trial: NCT00486356
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002631
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03036852
Drug: SOF/VEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100 mg fixed-dose combination (FDC) tablet(s) administered orally once daily
Trial: NCT00363571
Drug: GTN, Diamox
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00129285
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 400 mg/day
Trial: NCT04145076
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two oral doses of placebo.
Trial: NCT02409433
Drug: Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the phenytoin group will receive a loading dose of 20 mg/K IV, maximum of 2000 mg, given over 60 min. and will be started on a maintenance dose of 5 mg/K/day.
Trial: NCT02065492
Drug: Standard Chelation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This will comprise of standard chelation drugs (Deferasirox or Deferoxamine or Combination of Deferoxamine and Deferiprone).The dosage and drug used will depend on ferritin levels and individual requirement, as determined by the treating hematologist and will be in accordance with the Iron chelation guidelines from Pakistan Thalassemia Society.
Trial: NCT03068897
Drug: Ibuprofen 600 mg
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen
Trial: NCT01998061
Drug: EGFR tyrosine kinase inhibitor
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm A
Trial: NCT01998061
Drug: EGFR tyrosine kinase inhibitor with chemotherapy
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm B
Trial: NCT02782845
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The choice of CT will be as per standard of care and protocol does not specify any particular CT drug.
Trial: NCT02782845
Drug: Immunochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The choice of ICT will be as per standard of care and protocol does not specify any particular ICT drug.
Trial: NCT04648917
Drug: Caffeic acid
RxNorm normalized name: CAFFEIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 patients will receive coffeic acid treatment: 100-200mg, tid, po, 2 weeks treated then 1 week black interval(weight \>50kg, 200mg per time, weight \< or =50kg, 100mg per time)
Trial: NCT03657836
Drug: Standard antibiotic therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given standard therapy antibiotics cefuroxime and ceftriaxone for up to 7 days period.
Trial: NCT03415503
Drug: Medox® Anthocyanin capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were orally administered Medox® capsules daily for 12 weeks.
Trial: NCT00484341
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin: 60 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion) on day 1 every 3 weeks for a maximum of 6 cycles or until cumulative dose of 550 mg/m²
Trial: NCT02063685
Drug: Observation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: not maintenance therapy and followed-up with MRD monitoring.
Trial: NCT02063685
Drug: Standard Maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab 375 mg/m² every 2 months for 2 years. Maintenance will have to be started no more than 12 weeks after the last induction chemoimmunotherapy infusion.
Trial: NCT01725802
Drug: Levodopa/carbidopa solution for SC administration
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01725802
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01094834
Drug: DWP05195
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets, oral administration, multiple administration
Trial: NCT00777959
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three tablets of matching placebo to ridaforolimus administered daily for 5 consecutive days each week followed by 2 days without matching placebo and on 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.
Trial: NCT00938613
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nasal spray, one spray per nostril at time 0
Trial: NCT02457247
Drug: Calcichew D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3)
Trial: NCT02457247
Drug: Adcal-D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adcal-D3 (Calcium 600mg/400 IU Vitamin D3)
Trial: NCT02457247
Drug: Kalcipos-D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kalcipos-D (Calcium 500mg/800 IU Vitamin D3)
Trial: NCT01239173
Drug: AVLOCARDYL
RxNorm normalized name: Avlocardyl Retard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
Trial: NCT01239173
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
Trial: NCT01420510
Drug: Placebo vaginal gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of a placebo vaginal gel
Trial: NCT04464551
Drug: [14C]D-0316 suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before administration, the drug preparation was placed at room temperature, and 40ml drinking water was added into each bottle to prepare suspension for the subjects to take. 40ml pure water was injected again. After washing the container, the subjects took orally. Repeat the previous step, and then used 160ml purified water. After the administration container was moistened for several times, the subjects took all the moistening lotion. Pay attention not to splash the liquid during mixing outside the bottle
Trial: NCT04153084
Drug: PEG-3350 with electrolytes
RxNorm normalized name: PEG-3350 with Electrolytes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The low volume electrolytes PEG will be administered at a 4 mg/kg dose the day before the procedure in 4-8 hours.
Trial: NCT03931226
Drug: Drug consumption
RxNorm normalized name: DRUGS FOR CONSTIPATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: number of Daily Defined Doses (DDDs) of medications prescribed and given to children in connection with the indication of the spa treatment
Trial: NCT00811720
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as-needed use, tablets, orally, 6 months
Trial: NCT00889707
Drug: PRX302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRX302 will be administered at a volume equivalent to 20% of the prostate volume and at a fixed concentration. Treatment will be administered through 1 injection into the transition zone of each lobe of the prostate. A minimum of 2 deposits will be made in the transition zone into each of the right and left lobes of the prostate, with a minimum of 1.0 mL per deposit.
Trial: NCT00889707
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRX302 will be administered at a volume equivalent to 20% of the prostate volume and at a fixed concentration. Treatment will be administered through 1 injection into the transition zone of each lobe of the prostate. A minimum of 2 deposits will be made in the transition zone into each of the right and left lobes of the prostate, with a minimum of 1.0 mL per deposit.
Trial: NCT02590536
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03046836
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT01293136
Drug: Intravenous opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whatever opioids prescribed
Trial: NCT02156024
Drug: Gastrodia and Uncaria Drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrodia and Uncaria Drink, 1 dose at a time, twice a day, duration: 4 weeks
Trial: NCT02067143
Drug: Cycle 1 Induction
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02067143
Drug: Cycle 2 Induction / Early consolidation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02067143
Drug: Cycle 3 Early consolidation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02067143
Drug: Cycle 4 Consolidation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02067143
Drug: Cycle 5 Consolidation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02067143
Drug: Cycle 6 Consolidation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02067143
Drug: Cycle 7 Consolidation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02067143
Drug: Cycle 8 Reinduction
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03123770
Drug: Pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a new kind of doxorubicin
Trial: NCT03123770
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: traditional chemotherapy drug
Trial: NCT02264743
Drug: Femoston Conti
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose oral E2/D \[Oestradiol 17β 0.5mg/dydrogesterone 2.5 mg\] oral Femoston Conti 0.5mg Estradiol\&Dydrogesterone vs Oestradiol\&Norethisterone acetate
Trial: NCT02264743
Drug: EVOREL® CONTI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trans-dermal Estradiol 25mcg/norethisterone acetate 85 mcg 1/2 an Evorel Conti patch
Trial: NCT02390492
Drug: Period 1 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oral ipatasertib followed 1 hour later by 80-mcg/800-nCi intravenous \[14C\]-ipatasertib on Day 1 of study
Trial: NCT03570346
Drug: Hemay005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized into 3 dose groups orally twice daily.
Trial: NCT03570346
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized into 3 dose groups orally twice daily.
Trial: NCT03711487
Drug: Foeniculum Vulgare Seed Ironing
RxNorm normalized name: FOENICULUM VULGARE (FENNEL) SEED EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stir-fry 500 grams of Foeniculum vulgare seeds until the aroma overflows. Put them into a cotton bag. Ironing therapy put the bag on abdomen after the temperature is suitable, 30 minutes per time, twice daily on postoperative days 2 to 3. The medicine bag can be heated and reused after it cool down.
Trial: NCT04240106
Drug: Aromatase Inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase Inhibitors beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
Trial: NCT01520467
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo tablet /day administered orally for 18 months.
Trial: NCT00803868
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo matching study drug up to 1mg po bid
Trial: NCT04400682
Drug: AVIGAN 200 MG Film Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVIGAN is containing 200 mg favipiravir manufactured by Toyama, Japan
Trial: NCT04268069
Drug: PL9643 Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PL9643 Ophthalmic Solution as topical ophthalmic drops administered bilaterally for 12 weeks.
Trial: NCT04268069
Drug: Placebo Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution as topical ophthalmic drops administered bilaterally for 12 weeks.
Trial: NCT04410159
Drug: Essential oils
RxNorm normalized name: essential oils
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gargle
Trial: NCT01361217
Drug: Fluoxetine, Lovastatin, Omeprazole, caffeine, midazolam, dextromethorphan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1x20mg oral fluoxetine capsules by mouth daily on Study Day 5, then 3x20mg fluoxetine capsules by mouth daily on Study Days 6 through 18.~On study day 1 and study day 18, 100mg caffeine, 2mg midazolam, 30mg dextromethorphan and 20mg omeprazole (enteric coated formulation) orally with 250mL of water.~On study day 3 and study day 20 20mg of lovastatin with 250mL of water.
Trial: NCT03204877
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral capsules
Trial: NCT03973112
Drug: HLX10 3mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-PD-1
Trial: NCT03973112
Drug: HLX04 5mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-VEGF, a biosimilar to Avastin
Trial: NCT03973112
Drug: HLX04 10mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-VEGF, a biosimilar to Avastin
Trial: NCT02735421
Drug: ABPO Forte Gel
RxNorm normalized name: Carni Q-Gel Forte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants applied Adapalene 0.3% - Benzoyl peroxide (BPO) 2.5% gel (ABPO Forte) topically to the affected areas once daily for 24 weeks in Part 1 and for 48 weeks in Part 2.
Trial: NCT01097018
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 BID/ Days 1-14
Trial: NCT01097018
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 pill daily x 21 days
Trial: NCT00625859
Drug: GSK189075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK189075 will be available as film-coated tablets with a dose of 250 milligrams.
Trial: NCT00625859
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets will be given to subjects.
Trial: NCT02246673
Drug: RDEA3170 15 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02246673
Drug: RDEA3170 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02246673
Drug: RDEA3170 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02246673
Drug: RDEA3170 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02735421
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants applied placebo matched to ABPO Forte gel topically to the affected areas once daily for 24 weeks in Part 1 and 48 weeks in Part 2.
Trial: NCT02962245
Drug: regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: such as 5-ASA,immunomodulating/suppressive agents or Anti-TNF therapy
Trial: NCT02359032
Drug: ASP6858
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT02359032
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT03429738
Drug: Ibuprofen/Pseudoephedrine HCl 200/30 mg Film-Coated Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental drug
Trial: NCT03429738
Drug: RhinAdvil Rhume 200 mg/30 mg Film-Coated Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Comparator
Trial: NCT00849862
Drug: Keppra®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg Tablet
Trial: NCT01048398
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intervention: intravenous paracetamol 1g and remifentanil 1mg/100ml in 100ml of 0.9% saline.
Trial: NCT01861665
Drug: Marcaine- 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marcaine 0.25% administered pre-incision.
Trial: NCT01861665
Drug: Marcaine 0.25%.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marcaine 0.25% administered post-incision.
Trial: NCT01707953
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule to mimic midodrine
Trial: NCT02549989
Drug: LY3023414
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients will take LY3023414 200 mg orally twice a day. Each cycle will be 21 days in duration. Patients will receive study treatment until disease progression, intolerable toxicity, elective withdrawal from the study, study completion, or study termination